Sun Pharma Adv Resrc Peer Comparison
NSE: SPARC | BSE: 532872
₹201.19
₹4.21
(2.14%)
As on 02-Sep-2026 11:49IST
Market cap
₹6,387 Cr
Revenue (TTM)
₹1,909 Cr
P/E Ratio
4
P/B Ratio
4.8
Div. Yield
0 %
Edit
| Sun Pharma Adv Resrc | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
6,387 | 30,075 | 30,128 | 28,384 | 25,980 |
Revenue (₹ Cr) |
1,909 | 3,564 | 1,936 | 9,205 | 1,462 |
Net Profit (₹ Cr) |
1,584.29 | 414.00 | 288.22 | -371.81 | 387.35 |
Net Margin (%) |
81.88 | 11.23 | 14.79 | -3.93 | 26.01 |
RoE (%) |
-- | 8.38 | 29.77 | -3.85 | 25.18 |
Price to Earnings |
4.03 | 73.53 | 104.53 | -- | 67.27 |
Price-To-Book |
4.85 | 5.97 | 22.44 | 3.55 | 15.06 |
Income Statement (₹ Cr)
| Sun Pharma Adv Resrc | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,909.45 | 3,564.00 | 1,935.80 | 9,205.28 | 1,461.80 |
|
Total Income
|
1,934.92 | 3,686.00 | 1,948.58 | 9,449.59 | 1,489.25 |
|
Total Expenditure
|
293.58 | 2,792.00 | 1,485.56 | 8,195.15 | 919.25 |
|
EBITDA
|
1,615.87 | 772.00 | 450.24 | 1,010.13 | 542.56 |
|
Depreciation
|
9.73 | 226.00 | 50.83 | 857.51 | 37.68 |
|
EBIT
|
1,606.14 | 546.00 | 399.41 | 152.62 | 504.88 |
|
Interest
|
36.07 | 217.00 | 40.84 | 342.73 | 3.77 |
|
Other Income
|
25.47 | 122.00 | 12.78 | 244.31 | 27.45 |
|
Exceptional Items
|
-12.36 | 12.00 | 0.00 | -216.88 | 0.00 |
|
Profit before Tax
|
1,583.18 | 463.00 | 371.35 | -162.68 | 528.56 |
|
Provision for Tax
|
0.00 | 49.00 | 83.14 | 209.13 | 141.21 |
|
Profit after Tax
|
1,583.18 | 414.00 | 288.22 | -371.81 | 387.35 |
Liabilities (₹ Cr)
| Sun Pharma Adv Resrc | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
1,333.58 | 4,940.00 | 1,288.82 | 8,162.62 | 1,653.56 |
|
Minority Interest
|
0.00 | -5.00 | 0.00 | 0.00 | -1.13 |
|
Non-Current Liabilities
|
77.58 | 1,712.00 | 202.03 | 5,044.14 | 42.40 |
|
Current Liabilities
|
756.82 | 1,622.00 | 835.87 | 4,758.28 | 230.82 |
|
Total Liabilities
|
-- | 8,578.00 | 2,326.71 | 17,723.32 | -- |
Assets (₹ Cr)
| Sun Pharma Adv Resrc | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
157.45 | 5,343.00 | 519.60 | 10,211.52 | 1,026.85 |
|
Current Assets
|
1,861.38 | 2,606.00 | 1,681.81 | 7,191.66 | 881.27 |
|
Total Assets
|
-- | 8,578.00 | 2,326.71 | 17,723.32 | -- |
|
Total Debt*
|
-- | 2,125.00 | 259.37 | 5,495.48 | 26.49 |
|
Net Current Assets
|
1,104.56 | 984.00 | 845.94 | 2,433.38 | 650.46 |
|
Contingent Liabilities
|
-- | 768.26 | 19.09 | 95.72 | 17.25 |
Cashflow (₹ Cr)
| Sun Pharma Adv Resrc | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-- | 390.00 | 205.05 | 1,652.60 | 292.17 |
|
Cash Flow from Investing Activities
|
-- | -241.00 | -409.72 | -826.03 | -265.94 |
|
Cash from Financing Activities
|
-- | -54.00 | 283.07 | -38.98 | 4.10 |
|
Net Cash Inflow / Outflow
|
-- | 95.00 | 78.39 | 787.59 | 30.33 |
Ratios
Profitability Ratios
| Sun Pharma Adv Resrc | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-- | 6.79 | 29.22 | 1.24 | 32.42 |
|
ROE (%)
|
-- | 8.38 | 29.77 | -3.85 | 25.18 |
|
ROA (%)
|
126.79 | 4.94 | 24.77 | -2.21 | 21.93 |
|
EBIT Margin (%)
|
84.12 | 15.32 | 20.63 | 1.66 | 34.54 |
|
Net Margin (%)
|
81.82 | 11.23 | 14.79 | -3.93 | 26.01 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Sun Pharma Adv Resrc | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
2,855.80 | 18.37 | 46.65 | 0.78 | 40.90 |
|
EBIT Growth (%)
|
644.29 | 252.26 | 62.13 | -70.53 | 124.50 |
|
Net Profit Growth (%)
|
627.01 | 377.85 | 89.49 | -1,383.43 | 104.15 |
|
EPS Growth (%)
|
631.12 | 1,001.33 | 78.60 | -484.84 | 42.32 |
|
Book Value Growth (%)
|
-- | 13.47 | 144.31 | 0.33 | 26.03 |
Valuation Ratios
| Sun Pharma Adv Resrc | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Price / Earnings
|
4.00 | 75.47 | 102.93 | -90.71 | 67.27 |
|
Price / Book Value
|
4.87 | 5.97 | 22.44 | 3.55 | 15.06 |
|
Dividend Yield (%)
|
0.00 | 0.00 | 0.08 | 0.00 | 0.08 |
|
EV/EBITDA
|
4.30 | 40.85 | 66.72 | 32.20 | 47.52 |
|
Market Cap (₹ Cr)
|
-- | 19,071.62 | 12,753.19 | 18,108.89 | 20,944.75 |
Solvency Ratios
| Sun Pharma Adv Resrc | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 0.31 | 0.11 | 0.53 | 0.02 |
|
Short term debt to equity ratio
|
-- | 0.09 | 0.05 | 0.09 | 0.02 |
|
Current Ratio
|
2.46 | 1.61 | 2.01 | 1.51 | 3.82 |
|
Quick Ratio
|
2.46 | 1.06 | 1.14 | 0.87 | 2.82 |
|
Interest Coverage
|
44.89 | 3.13 | 10.09 | 0.53 | 141.16 |
Operating Efficiency Ratios
| Sun Pharma Adv Resrc | Wockhardt | Rubicon Research | Piramal Pharma | Acutaas Chemicals | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
0.43 | 16.50 | 26.28 | 23.44 | 24.80 |
|
Asset Turnover
|
1.53 | 0.43 | 1.66 | 0.55 | 0.83 |
|
Receivable days
|
-- | 58.75 | 40.13 | 78.20 | 88.98 |
|
Inventory Days
|
-- | 75.82 | 60.29 | 93.30 | 56.04 |
|
Payable days
|
-- | 186.21 | 232.47 | 226.14 | 99.95 |
|
Cash Conversion Cycle
|
-- | -51.64 | -132.04 | -54.64 | 45.07 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
